del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia

Cancer Genetics and Cytogenetics

Volumn 192, Issue 1, 2009, Pages 18-23

  Yin, C Cameron ^a   Abruzzo, Lynne V ^a   Qiu, Xiaoyan ^a   Apostolidou, Effrosyni ^a   Cortes, Jorge E ^a   Medeiros, L Jeffrey ^a   Lu, Gary ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; BOSUTINIB; CYCLOPHOSPHAMIDE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; HOMOHARRINGTONINE; IDARUBICIN; IMATINIB; INTERFERON; MESNA; METHOTREXATE; NILOTINIB; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER GROWTH; CHROMOSOME 15Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DEATH; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 15; CLONE CELLS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HUMANS; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED;

EID: 65749090396     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.02.017     Document Type: Article

References (36)

1. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
2. Deininger M.W., and Goldman J.M. Chronic myeloid leukemia. Curr Opin Hematol 5 (1998) 302-308
3. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 340 (1999) 1330-1340
4. Sawyers C.L. Signal transduction pathways involved in BCR/ABL transformation. Baillieres Clin Haematol 10 (1997) 223-231
5. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 341 (1999) 164-172
6. Deininger M., Goldman J.M., and Melo J. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343-3356
7. Oudat R., Khan Z., and Glassman A.B. A unique complex variant Philadelphia chromosome translocation in a patient with typical chronic myelogenous leukemia. Arch Pathol Lab Med 125 (2001) 437-439
8. Sacchi S., Kantarjian H., O'Brien S., Cortes J., Rios M.B., Giles F.J., Beran M., Koller C.A., Keating M.J., and Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86 (1999) 2632-2641
9. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 11 Suppl. 1 (1993) 11-15
10. Yin C.C., Medeiros L.J., Glassman A.B., and Lin P. t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. Am J Clin Pathol 121 (2004) 836-842
11. Merzianu M., Medeiros L.J., Cortes J., Yin C., Lin P., Jones D., Glassman A., Kantarjian H., and Huh Y. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol 124 (2005) 807-814
12. Yin C.C., Cortes J., Barkoh B., Hayes K., Kantarjian H., and Jones D. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer 106 (2006) 1730-1738
13. Yin C.C., Jones D., Cortes J.E., Kantarjian H., Merzianu M., Medeiros L.J., and Bueso-Ramos C.E. Type B core binding factor β/smooth muscle myosin heavy chain fusion transcript in myeloid blast phase of chronic myeloid leukemia: correlation with nuclear and cytoplasmic localization of the fusion protein. Clin Leuk 2 (2008) 257-260
14. Provan A., Majer R.V., Herbert A., and Smith A.G. del(15)(q11q15) associated with transformation of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 55 (1991) 35-38
15. Hda N., Chadli B., Bousfiha A., Trachli A., Harif M., and Benslimane A. Cytogenetic survey of 53 Moroccan patients with acute myeloblastic leukemia. Cancer Genet Cytogenet 86 (1996) 124-128
16. Yahata N., Ohyashiki K., Iwase O., Kimura Y., Kodama A., Fukutake K., and Toyama K. A sole del(15q) anomaly in post-myelodysplasia acute myeloid leukemia. Leuk Res 22 (1998) 845-847
17. Dierlamm J., Schilling G., Michaux L., Hinz K., Penas E.M., Seeger D., Hagemeijer A., and Hossfeld D.K. Deletion of chromosome 15 represents a rare but recurrent chromosomal abnormality in myelocytic malignancies. Cancer Genet Cytogenet 144 (2003) 1-5
18. Saunders K., Williams Y., Aldouri M., Telford N., and Czepulkowski B. Deletion of chromosome arm 15q and hitherto unreported duplication of del(15q) in myeloid disorders. Cancer Genet Cytogenet 151 (2004) 146-151
19. Lu G., Yin C.C., Medeiros L.J., and Abruzzo L.V. Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature. Cancer Genet Cytogenet 188 (2009) 118-123
20. Heerema N.A., Sather H.N., Sensel M.G., La M.K., Hutchinson R.J., Nachman J.B., Reaman G.H., Lange B.J., Steinherz P.G., Bostrom B.C., Gaynon P.S., and Uckun F.M. Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer 94 (2002) 1102-1110
21. Lawler S.D., O'Malley F., and Lobb D.S. Chromosome banding studies in Philadelphia chromosome positive myeloid leukaemia. Scand J Haematol 17 (1976) 17-28
22. Fleischman E.W., Prigogina E.L., Volkova M.A., Frenkel M.A., Zakhartchenko N.A., Konstantinova L.N., Puchkova G.P., and Balakirev S.A. Correlations between the clinical course, characteristics of blast cells, and karyotype patterns in chronic myeloid leukemia. Hum Genet 58 (1981) 285-293
23. Pintado T., Ferro M.T., San Román C., Mayayo M., and Laraña J.G. Clinical correlations of the 3q21;q26 cytogenetic anomaly: a leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 55 (1985) 535-541
24. Akiyoshi T.T., Kimura N., Uike N., Kozuru M., Tamura K., Takihara Y., Hisano S., Nishimura J., and Kikuchi M. Genotypic and cytogenetic study of acute myelocytic leukemia and chronic myelocytic leukemia in blast crisis: Specific δ rearrangement pattern does not involve Jδ gene locus. Leuk Res 15 (1991) 683-691
25. Kohno S., Van Den Berghe H., and Sandberg A.A. Chromosomes and causation of human cancer and leukemia: XXXI. Dq- deletions and their significance in proliferative disorders. Cancer 43 (1979) 1350-1357
26. Vardiman J.W., Melo J.V., Baccarani M., and Thiele J. Chronic myelogenous leukaemia, BCR-ABL1 positive. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., and Vardiman J.W. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed (2008), IARC Press, Lyon 32-37
27. Hao S., Sanger W., Onciu M., Lai R., Schlette E.J., and Medeiros L.J. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol 15 (2002) 266-272
28. ISCN 2005. an international system for human cytogenetic nomenclature (2005). In: Shaffer L.G., and Tommerup N. (Eds) (2005), S. Karger, Basel
29. Luthra R., Sanchez-Vega B., and Medeiros L.J. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol 17 (2004) 96-103
30. Heim S., and Mitelman F. Cancer cytogenetics: chromosomal and molecular genetic aberrations of tumor cells. 2nd ed. (1995), Wiley-Liss, New York pp.33-68
31. Calabretta B., and Perrotti D. The biology of CML blast crisis. Blood 103 (2004) 4010-4022
32. Kantarjian H., O'Brien S., Cortes J., Wierda W., Faderl S., Garcia-Manero G., Issa J.P., Estey E., Keating M., and Freireich E.J. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113 (2008) 1933-1952
33. Jabbour E., Cortes J.E., and Kantarjian H.M. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer 112 (2008) 2112-2118
34. Ma W., Stafford L.J., Li D., Luo J., Li X., Ning G., and Liu M. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. J Cell Biochem 100 (2007) 1376-1386
35. Park W.S., Park J.Y., Oh R.R., Yoo N.J., Lee S.H., Shin M.S., Lee H.K., Han S., Yoon S.K., Kim S.Y., Choi C., Kim P.J., Oh S.T., and Lee J.Y. A distinct tumor suppressor gene locus on chromosome 15q21.1 in sporadic form of colorectal cancer. Cancer Res 60 (2000) 70-73
36. Rhiem K., Klein A., Munch M., Kreutzfeld R., Ramser J., Wardelmann E., Schackert G., Von Deimling A., Wiestler O.D., and Schmutzler R.K. Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. Int J Cancer 106 (2003) 74-77